ABSTRACT

Introduction: There is limited data on the effects of biologic therapies on genital psoriasis and sexual activity. Recently, Ixekizumab was reported to be effective.

Aim: To compare the efficacy of ixekizumab and secukinumab for the treatment of genital psoriasis and sexual inadequacy in adult patients with moderate‐to‐severe psoriasis.

Patients and methods: We assessed adult patients with moderate-to-severe psoriasis having genital involvement. They were randomly assigned in a 1:1 ratio to receive either ixekizumab (80 mg/2 weeks after 160-mg initial dose) or secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks). The severity was assessed using Genital Psoriasis Symptoms Scale (GPSS), and impact on sexual health by evaluating the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ).

Results: Twenty eight patients on ixekizumab, and 26 on secukinumab showed improvement in genital psoriasis symptoms, beginning week 2 (GPSS total and individual items), and from week 4 onwards, improvement in sexual activity was seen with both drugs.

Conclusion: Both genital psoriasis symptoms and impact on sexual activity improved rapidly and significantly with both the IL-17 inhibitors. Limitations included small number of patients and lack of follow-up period.

摘要

简介：关于生物疗法对生殖器银屑病和性活动的影响的数据有限。最近，据报道，Ixekizumab 是有效的。

目的：比较 ixekizumab 和 secukinumab 治疗成人中重度银屑病患者生殖器银屑病和性功能不全的疗效。

患者和方法：我们评估了有生殖器受累的中度至重度银屑病成年患者。他们以 1:1 的比例随机分配接受 ixekizumab（160 mg 初始剂量后 80 mg/2 周）或苏金单抗（第 0、1、2、3 和 4 周皮下注射 300 mg，然后每 4 周一次） ）。使用生殖器银屑病症状量表 (GPSS) 评估严重程度，并通过评估马萨诸塞州总医院性功能问卷 (MGH-SFQ) 评估对性健康的影响。

结果： 28 名 ixekizumab 患者和 26 名 secukinumab 患者从第 2 周开始（GPSS 总和个别项目）显示生殖器银屑病症状有所改善，从第 4 周开始，两种药物的性活动都得到改善。

结论: 两种 IL-17 抑制剂都能迅速和显着改善生殖器银屑病症状和对性活动的影响。局限性包括患者数量少和缺乏随访期。